Monitoring the Effectiveness of an Antibiotic Against MRSA with the MolecuLight *i:X*™

Methicillin resistant *Staphylococcus aureus* (MRSA) infections are difficult to treat with standard types of antibiotics and are therefore more dangerous and more costly to the healthcare system.

Clinical Synopsis: Although Negative Pressure Wound Therapy (NPWT) had signficantly reduced wound size in this non-healing venous leg ulcer, all treatments targeting MRSA infection had been unsuccessful. This prompted prescription of a newly available oral antibiotic. After one week of treatment, MolecuLight *i:X* fluorescence images revealed a significant decrease in bioburden, providing immediate feedback on antibiotic effectiveness.

Practitioner

Rose Raizman RN-EC, MSc, with over 19 years of experience, leads the Save Our Skin (SOS) team at Scarborough & Rouge Hospital located in Toronto, Canada, to combat pressure ulcers of hospital inpatients. She also oversees the wound care clinic for inpatients and outpatients.

Patient Condition

50 year old male patient with a venous leg ulcer (>1 year) on left medial ankle. Wound presented with heavy drainage and a MRSA infection that had persisted over many months of care, despite numerous antibiotics and antimicrobials. Patient's wound received regular cleaning and debridement and was being treated with negative pressure wound therapy.

US FDA De Novo approval pending – the MolecuLight *i:X*™ Imaging Device is not available in the US.

MolecuLight
LOOK TO HEAL®

Figure 1: Standard Imaging Mode.™



Figure 2: Fluorescence Imaging Mode.™ The red colour suggests a presence of bacteria.

Figure 3: Standard Imaging Mode™ after one week of treatment.



Figure 4: Fluorescence Imaging Mode™ after one week of treatment. The noticeable decrease in red color suggests significant decrease in bacterial burden.

MolecuLight *i:X*™

Wound Intelligence Device

The MolecuLight ***i:X*** allows clinicians to quickly, safely and easily visualize bacteria[1] and measure wounds[2] at the point of care so they have maximum insights for accurate treatment selection and accelerated healing.[1]

Testimonial

"I had tried numerous treatments targeting this patient's MRSA, none of which were effective. The MolecuLight images demonstrated a reduction in bacteria after one week of antibiotic treatment."

— Rose Raizman RN-EC, MSc

View MolecuLight ***i:X***™ in action.
Visit moleculight.com

+1.647.362.4684
Toll Free 1.877.818.4360 (Canada)
info@moleculight.com

Follow us:

Bacteria appear red in image

MolecuLight
LOOK TO HEAL®

References:
Images provided by Rose Raizman, RN-EC, MSc, Scarborough & Rouge Hospital, ON, Canada
MolecuLight Clinical Case 0020b.

1. DaCosta RS *et al*. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3).
2. MolecuLight Inc. Case Study 0051 Track Wound Size and Bacterial Presence with the MolecuLight ***i:X***. 2016.

The MolecuLight *i:X*™ Imaging Device is approved by Health Canada (Medical License #95784) and has CE marking (Certificate #G1160292355002) for sale in Canada and the European Union.
US FDA De Novo approval pending – the MolecuLight ***i:X*** Imaging Device is not available in the US.